Atlas Trials

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical trial NCT06479759 · UNKNOWN

Trial details

NCT number
NCT06479759
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLCPD-1
Start date
2024-01-12
Primary completion
2025-06-12
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.